Data at JIM show bio-engineered stent may be good choice for patients not suitable for antiplatelet therapy


Clinical data presented at the Joint Interventional Meeting (JIM) 2010 in Rome provide further evidence that Orbus Neich’s Genous stent could be a treatment of choice for patients not suitable for long-term dual antiplatelet therapy. The investigator-initiated, 50 patient, multicentre study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.


Presented by Giuseppe M. Sangiorgi, EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy, three-month follow-up data from the Genous in patients with reduced antiplatelet therapy study show no stent thrombosis of the lesions treated with a Genous stent, one case of myocardial infarction, not related to Genous stent implantation, and no sudden cardiac death.

“In our institution we use Genous for patients not suitable for prolonged dual antiplatelet therapy or in whom we feel it may have problems with compliance,” said Sangiorgi. “For these patients and based on the extremely promising results we have had with Genous stent utilisation, I believe that this stent can be the optimal compromise we can offer to our patients in terms of efficacy and safety as compared to bare metal or drug-eluting stents”.

The study population included patients with de novo coronary artery lesions located in the secondary branch vessel. The primary endpoint evaluated the absence of any occlusion and stent thrombosis of the Genous stent within three months, including the angiographic evidence of stent occlusion, myocardial infarction in the area of the stented vessel and sudden cardiac death not attributed to other causes.